ClinicalTrials.gg

Program

YTS109

A development code. Also written as “YTS109 cell” and “YTS109 cell injection”.

Its studies are mostly in Lupus Nephritis · Anemia, Hemolytic, Autoimmune · Lupus Erythematosus, Systemic, led by China Immunotech (Beijing) Biotechnology.

Furthest: phase 1, since Apr 16, 20258 company-led studies, 6 open or runningNext primary completion: Nov 24, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
China Immunotech (Beijing) Biotechnology86 open or runningphase 1since Apr 16, 2025Apr 16, 2025Nov 24, 2026phase 1 · NCT07236762

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 16, 2025First study: phase 1 study in Lupus NephritisFirst studyNCT06943937 · 2 enrolled · China
  2. May 9, 2025Phase 1 study in Lupus Erythematosus, SystemicNCT06978647 · 12 planned · China
  3. Jul 11, 20252 phase 1 studiesNCT07075484, NCT07104721
  4. Aug 8, 2025Phase 1 study in Lupus Erythematosus, SystemicNCT07123519 · 18 planned · China
  5. Nov 15, 20252 phase 1 studies in Lupus Erythematosus, SystemicNCT07236801, NCT07236762
  6. Mar 2, 2026Phase 1 study in Anemia, Hemolytic, AutoimmuneNCT07453836 · 13 planned · China

Ahead

  1. Nov 13, 2026Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT07236801
  2. Nov 24, 2026Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT07236762
  3. Mar 18, 2027Primary completion: phase 1 study in Anemia, Hemolytic, AutoimmuneNCT07453836
  4. May 19, 2027Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT06978647

TargetBeta

CD19 →read by rule
“YTS109 is a universal allogeneic CD19-targeting STAR-T cell therapy designed to efficiently eliminate CD19+ B cells and attenuate pathogenic autoimmune responses.”study text, by rule · the study

Other programs on CD19

ProgramCompanyFurthest phaseStudies
blinatumomabruleAmgenphase 429
inebilizumabruleAmgenphase 419
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012FAstraZenecaphase 312
axicabtagene ciloleucelruleGilead Sciencesphase 310
surovatamigAstraZenecaphase 310
lisocabtagene maraleucelruleBristol-Myers Squibbphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
obexelimabzenas-biopharma-usa-llcphase 37
Autologous Anti-CD19 CAR-T Cells CABA-201rulecabaletta-biophase 36
zolacabtagene autoleucelBristol-Myers Squibbphase 36
Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753ruleGilead Sciencesphase 32
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07453836Anemia, Hemolytic, Autoimmune · China1Not yet recruitingMar 18, 202713
NCT07236801Lupus Erythematosus, Systemic · China1RecruitingNov 13, 202618
NCT07236762Lupus Erythematosus, Systemic · China1RecruitingNov 24, 202618
NCT07123519Lupus Erythematosus, Systemic · China1RecruitingAug 13, 202718
NCT07104721Lupus Erythematosus, Systemic · China1RecruitingAug 4, 202618
NCT07075484Anemia, Hemolytic, Autoimmune · China1CompletedDec 30, 20257
NCT06978647Lupus Erythematosus, Systemic · China1RecruitingMay 19, 202712
NCT06943937Lupus Nephritis · China1TerminatedApr 25, 20262

How it is read

Names in the registry

  • “YTS109 cell”, 7 entries
  • “YTS109 cell injection”, 1 entry

Codes read as this program: YTS109.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.